Shots:

• The BT destination follows P-lll DAPA-CKD assessing Farxiga (10mg- qd) + SOC vs PBO in 4-304 patients with CKD Stages 2-4 and elevated urinary albumin excretion- with/ out T2D across 21 countries
• Results: 39% reduction in the composite measure of worsening of renal function or risk of CV or renal death; 31% reduction in death from any cause
• Farxiga (PO- qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss- and BP reduction

­ Ref: AstraZeneca | Image: Mint